Leukemia News

More than 2 years after the COVID-19 pandemic began, new treatments, vaccines and preventive measures have improved safety and disease outcomes for patients with cancer, according to a speaker at Chemotherapy Foundation Symposium.

In this edition, the importance of vaccination after cell therapy, artificial intelligence may help predict cardiotoxicity, experimental breast cancer vaccine generates immune response, and more.

Early referral to transplantation can increase access to transplant and cell therapies, as well as improve outcomes among patients with hematologic malignancies, according to a speaker at Chemotherapy Foundation Symposium.

Socioeconomic status had no impact on complete remission rates or overall survival among younger patients who received chimeric antigen receptor T-cell therapy for B-cell acute lymphoblastic leukemia, study results showed.

Dual administration of CD19- and CD22-directed chimeric antigen receptor T cells conferred a 99% complete remission rate in younger patients with relapsed or high-risk B-cell acute lymphoblastic leukemia, phase 2 study results showed.

I-131 apamistamab induced durable complete remissions for adults with active relapsed or refractory acute myeloid leukemia, according to topline data released by the agent’s manufacturer.

Luspatercept-aamt improved red blood cell transfusion independence with a concurrent hemoglobin increase among certain patients with myelodysplastic syndrome, according to the agent’s manufacturer.

Carl H. June, MD, will receive the inaugural Maria I. New International Prize for Biomedical Research.

Cancer death rates declined broadly between 2015 and 2019 in the United States as overall incidence remained generally stable, according to the Annual Report to the Nation on the Status of Cancer.

Four individuals have been elected to American Society of Hematology’s executive committee.